Glenmark Pharmaceuticals reported Q1FY27 revenue growth driven by strong sales in India, the US, and emerging markets. While profit and margins saw a slight dip, the company expects EBITDA margins to recover to 21-22% by the end of the fiscal year. ICICI Securities has maintained its hold rating on the stock with a target of ₹2,100.
Glenmark Pharmaceuticals reported its first-quarter financial results for FY27, showcasing a mixed performance that saw revenue surpass analyst expectations even as profit margins faced some pressure. The company reported a 15.5% year-over-year revenue increase in its domestic Indian market, while operations in the US and emerging markets grew by 8.5% and 27.7% respectively.
Operational Performance and Margin Trends
The revenue growth was supported by the launch of new products in India and the rollout of several items from the company's Monroe facility, including gFlovent, in the US market. Despite this growth, profitability metrics showed a decline. When adjusted for income from out-licensing, gross margins and EBITDA margins contracted by 122 basis points and 119 basis points respectively. A basis point is one-hundredth of a percentage point, meaning these contractions reflect a tighter spread between the company's costs and its earnings for the quarter.
Future Growth Triggers and Management Outlook
Looking ahead, the company management has projected a recovery in EBITDA margins to a range of 21-22% for FY27. Investors will be tracking the progress of its research pipeline, particularly the planned Investigational New Drug (IND) application for ISB 2301, which is expected to be filed later in the calendar year 2026. If the company moves forward with clinical trials in 2027, the potential out-licensing of this drug is viewed by market analysts as a significant catalyst for future financial performance.
Valuation and Market Context
ICICI Securities has maintained its hold rating on Glenmark Pharmaceuticals, setting a price target of ₹2,100. This valuation is derived using a 20x multiple on the company's estimated earnings per share for FY28, with an added value of ₹225 attributed specifically to its New Chemical Entity products. Investors may continue to monitor whether the company can successfully bridge the gap between current margin levels and its projected annual targets, as well as the execution timeline for its US product launches and research filings. Sustained demand in the domestic and emerging markets, alongside cost management efforts, will be essential for meeting these profitability goals in the coming quarters.